Effects of Pycnogenol ® in post-COVID-19 condition (PYCNOVID): A single-center, placebo controlled, quadruple-blind, randomized trial
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Post-COVID-19 condition (PCC) remains a public health challenge with limited treatment options.
Objective
To evaluate the effects of Pycnogenol ® , a French maritime pine bark extract with anti-inflammatory and antioxidative properties, versus placebo on patient-reported health status in individuals with PCC.
Design
Single-center, placebo-controlled, quadruple-blind, randomized trial. ClinicalTrials.gov, NCT05890534
Setting
German-speaking Switzerland.
Participants
Adults with PCC with at least one of the following symptoms: fatigue, post-exertional malaise, dyspnea, or brain fog.
Intervention
Daily dose of 200 mg Pycnogenol ® (50 mg capsules four times daily) or placebo for 12 weeks.
Measurements
The primary outcome was self-reported health status (EQ-VAS). Secondary outcomes included symptoms, quality of life, exercise capacity, physical activity and blood biomarkers.
Results
Between June 14, 2023, and July 5, 2024, 153 participants were randomized to receive Pycnogenol ® (n=75) or placebo (n=78). Participants reported persisting symptoms for a median duration of 101 weeks. Unadjusted median EQ-VAS increased by 5.4 units and 7.9 units in the in the Pycnogenol ® and placebo groups, respectively, with no difference observed between the groups (β=0.54, 95% CI -3.45 to 4.54, p=0.79). 31 adverse events occurred in the Pycnogenol ® group (11 probably related) and 18 in the placebo group (9 probably related). Three serious adverse events were reported, all unrelated to the study products. No between group differences were observed in secondary endpoints.
Limitation
The results may not be generalizable to individuals newly experiencing PCC.
Conclusion
Pycnogenol ® (200 mg daily) did not improve health status compared to placebo over 12 weeks in PCC. Both groups showed clinically relevant improvements, suggesting non-therapeutic effects.
Primary funding source
Horphag Research, Switzerland.
